A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia · Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
3 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 104 (planned)
- Started
- Dec 8, 2025
- Main results expected
- Mar 6, 2031
- Fully finished
- Sep 16, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1b: Number of Participants who Experienced Dose Limiting Toxicities (DLTs)
Measured over: Up to 29 days
Phase 1b: Number of Participants who Experienced Treatment-emergent Adverse Events (TEAEs)
Measured over: Up to approximately 7 months
Phase 1b: Number of Participants who Experienced Serious TEAEs
Measured over: Up to 2 years and 7 months
Phase 1b: Number of Participants who Experienced Treatment-related TEAEs
Measured over: Up to approximately 7 months
Phase 1b: Number of Participants who Experienced AEs of Interest (EOI)
Measured over: Up to approximately 7 months
Phase 2; R Cohort: Number of Participants who had Complete Remission/Complete Remission with Partial Hematological Recovery (CR/CRh) Within the First 2 Cycles
Measured over: Up to 70 days
Phase 2; M Cohort: Number of Participants who had CR with MRD Negative Response Within the First 2 Cycles
Measured over: Up to 70 days
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07134088 · record last updated 2026-10-05 · checked 2026-11-09 15:47 UTC